WƌŽďůĞŵůƂƐƵŶŐ Testfragen Sample Clauses

WƌŽďůĞŵůƂƐƵŶŐ Testfragen. Bitte bewerten Sie die folgenden Aussagen auf einer Xxxxx: 6. Ich versuche, mich mit den politischen Problemen und anderen Konsequenzen der von mir ǀŽƌŐĞƐĐŚůĂŐĞŶĞŶ sĞƌćŶĚ ĚĂŵŝƚ ĂŶĚĞƌĞ ŵĞŝŶĞ >ƂƐ ƵŶƚĞƌenƐ. ƚƺƚnj 7. Ich suche systematisch nach Themen, die in der ƵŬƵŶĨƚ ƉƌŽďůĞŵĂƚŝƐĐŚ 8. Ich stelle xxx xxxxx verschiedene Fragen zur Art des Problems. 9. EĂĐŚĚĞŵ ŵĞŝŶĞ >ƂƐƵŶŐ ŝ ich und konzentriere mich wieder auf meine ƌĞŐƵůćfgƌabĞenŶ. Ƶ 10. Eine Entscheidung ist das Ende meines WƌŽďůĞŵůƂƐƵŶŐƐƉƌŽnjĞƐƐĞ ϭ ƺďĞƌŚĂƵƉƚ Ŷ 2 selten, 3 Manchmal, 4 Oft, 5 Sehr oft. Auswertung nach Xxxxx 5-10 Sie neigen dazu, Probleme eher als Negative zu sehen, anstatt sie als Gelegenheiten zu sehen, ĂƵĨƌĞŐĞŶĚĞ ƵŶĚ ŶŽƚǁĞŶĚŝŐĞ sĞƌćŶĚĞƌƵŶŐĞŶ ŝŶƚƵŝƚŝǀĞƌ ĂůƐ ƐLJƐƚĞŵĂƚŝƐĐŚĞƌ͕ nƵgeŶn inĚd erĚŝĞƐ sĞƌŐĂŶŐĞŶŚĞŝƚ ŐĞĨƺŚƌƚ ŚĂďĞŶ͘ Dŝƚ ŵĞŚƌ mď ĚĞƌ >ĂŐĞ ƐĞŝŶ͕ ĚŝĞƐĞ ǁŝĐŚƚŝŐĞ &ćŚŝŐŬĞŝƚ (Lesen Sie unten, um zu beginnen.) 11-19 Ihre HerangehensǁĞŝƐĞ njƵƌ WƌŽďůĞŵůƂ-aƐndƵ-mŶissŐ". MaŝncƐhmƚa l ĞŝŶ ď ĨƵŶŬƚŝŽŶŝĞƌĞŶ /ŚƌĞ >ƂƐƵŶŐĞŶ ǁŝƌŬůŝĐŚ ŐƵƚ ƵŶĚ ^ŝĞ ĞƌŬĞŶŶĞŶ͕ ĚĂƐƐ ĞŝŶ ƐƚƌƵŬƚƵƌŝĞƌmƚĞ Prozess jedoch nicht immer. Wenn Sie an Ihrer Konsistenz arbeiten und sich an den Prozess binden, werden Sie deutliche Verbesserungen feststellen. (Lesen Sie unten, um zu beginnen.) 20-25 ^ŝĞ ƐŝŶĚ ĞŝŶ ƐĞůďƐƚďĞǁƵƐƐƚĞmƌd asWPrƌobŽleďm ůzuĞveŵrstůehƂenƐ, Ğ ĚŝĞ <ƌŝƚĞƌŝĞŶ Ĩƺƌ ĞŝŶĞ ŐƵƚĞ ŶƚƐĐŚĞŝĚƵŶŐ Weil Sie Probleme systematisch angehen, decken Sie jedes Mal das Wesentliche ab - und Ihre Entscheidungen sind durchdacht, gut geplant ƵŶĚ ŐƵƚ ƵŵŐĞƐĞƚnjƚ͘ ^ŝ WƌŽďůĞŵůƂƐƵŶŐƐĨćŚŝŐŬĞŝƚĞŶ ǁĞŝƚĞƌ ƉĞƌĨĞŬƚ Verbesserungsinitiativen in Ihrem Unternehmen nutzen.
AutoNDA by SimpleDocs

Related to WƌŽďůĞŵůƂƐƵŶŐ Testfragen

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Stability Testing Patheon may be requested to conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C to a Product Agreement. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. Patheon will give Client ail stability test data and results at Client’s request.

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Product Testing No later than [**] prior to a scheduled Delivery ARIAD US shall send to ARIAD SWISSCO the Delivery Documents for review. Following such review, unless within [**] of receipt of the Delivery Documents ARIAD SWISSCO gives written notice of rejection of the Product to be delivered, stating the reasons for such rejection, the Delivery shall proceed, and both Parties shall organize the same. Upon arrival at ARIAD SWISSCO nominated site it shall visually inspect the shipment of the Product to identify any damage to the external packaging. ARIAD SWISSCO may reject any shipment (or portion thereof) of the Product that is damaged by providing to ARIAD US reasonable evidence of damage within [**] after Delivery of such Product. If ARIAD SWISSCO does not so reject any shipment (or portion thereof) of the Product within [**] of Delivery of such Product, ARIAD SWISSCO shall be deemed to have accepted such shipment of the Product; provided, however, that in the case of the Product having any Latent Defect, ARIAD SWISSCO shall notify ARIAD US promptly once it becomes aware that a Product contains a Latent Defect and subsequently may reject such Product by giving written notice to ARIAD US of ARIAD SWISSCO’s rejection of such Product and shipping a representative sample of such Product or other evidence of Non-Conformance to ARIAD US within [**] after becoming aware of such Latent Defect, which notice shall include a description of the Latent Defect.

  • Positive Test Results In the event an employee tests positive for drug use, the employee will be provided, in writing, notice of their right to explain the test results. The employee may indicate any relevant circumstance, including over the counter or prescription medication taken within the last thirty (30) days, or any other information relevant to the reliability of, or explanation for, a positive test result.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!